Hepatitis B Virus-Related Polyarteritis Nodosa and Membranous Nephropathy

Mouthon, Luc; Deblois, Pierre; Sauvaget, F.; Meyrier, Alain; Callard, P; Guillevin, Loı̈c

doi:10.1159/000168844

Cited by 16 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating antigen-antibody complexes aggregate in the vessels. The renal pathology may be limited to medium-sized arteries with ischemic changes in the glomeruli [ 12 ].…”

Section: Hbv-associated Nephropathymentioning

confidence: 99%

Renal Impairment in Chronic Hepatitis B: A Review

et al. 2018

View full text Add to dashboard Cite

The liver plays a key role in the metabolism of proteins. Liver dysfunction affects many organs because it communicates with the spleen and all digestive organs through the portal vein. Additionally, the kidney is an organ that is closely related to the liver and is involved in liver diseases. Glomerulonephritis is an important extrahepatic manifestation of chronic hepatitis B virus (HBV) infection. Nucleos(t)ide analog (NA) therapy effectively suppresses HBV replication by inhibiting HBV polymerase, thus decreasing the levels of serum HBV-DNA and delaying the progression of cirrhosis. Although NA therapy is recommended for all patients with chronic HBV infection, regardless of the level of renal dysfunction, there is limited information on NA use in patients with chronic kidney disease. In addition, in patients with end-stage liver cirrhosis, hepatorenal syndrome can be fatal. Hence, we should take into account the stage of impaired renal function in patients with cirrhosis. The aims of this article are to review the epidemiology, clinical presentation, treatment, and prevention of HBV-associated nephropathy.

show abstract

“…Circulating antigen-antibody complexes aggregate in the vessels. The renal pathology may be limited to medium-sized arteries with ischemic changes in the glomeruli [ 12 ].…”

Section: Hbv-associated Nephropathymentioning

confidence: 99%

Renal Impairment in Chronic Hepatitis B: A Review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In support of this experience, there have been numerous published case reports in which HBV-PAN responded favorably to IFNa. [75][76][77][78][79][80][81][82][83][84][85][86] Behç et's Disease Behçet's disease is a complex multisystem illness characterized by mucocutaneous disease, ocular inflammation, central nervous system disease, and vasculitis. The mechanisms of pathogenesis in Behçet's disease are not well understood.…”

Section: Interferon-alphamentioning

confidence: 99%

Biologic Immunomodulatory Therapies in the Vasculitic Diseases

Langford

2004

Seminars in Respiratory and Critical Care Medicine

View full text Add to dashboard Cite

The expanding range of biologic agents capable of modulating the immune response has opened up a new realm for therapeutic exploration in the vasculitic diseases. Partnered with increasing knowledge regarding the mechanisms of vascular inflammation, these agents have raised the question as to whether it may be possible to treat systemic vasculitis syndromes by selectively targeting pathways involved in disease pathogenesis. The action of these agents to directly modulate specific immunologic components offers the potential not only to impact disease activity but also to reduce the risk of morbidity that can result from currently available treatment options. The study of biologic therapies in the vasculitides must, however, be approached with caution because unanticipated effects on disease activity and disease-specific toxicities can occur. The only biologic agent that has currently been shown to have therapeutic efficacy in a systemic vasculitis syndrome is interferon-alpha in the treatment of hepatitis C-associated cryoglobulinemic vasculitis. The use of biologic agents to treat other vasculitides remains investigational. Methodical evaluation of biologic agents prior to their use in general clinical practice is essential to understand their safety and efficacy. Rigorous, standardized investigations may also provide important insights into pathogenesis of the vasculitic diseases.

show abstract

“…Hepatitis B has been associated with a number of extra-hepatic manifestations which are believed to be mediated in part by altered immunological function. These conditions include: skin rashes [65], arthralgias [66], glomerulonephritis [67,70], cryoglobulinaemias [71], polyarteritis nodosa [69,72,73] and most recently, porphyria cutanea tarda [74]. This latter condition has been linked to HCV infection and the most recent investigation has also associated HBV.…”

Section: Clinical Featuresmentioning

confidence: 99%

Hepatitis B

BATE

Bollipo

1996

Drug and Alcohol Review

View full text Add to dashboard Cite

Hepatitis B remains a major public health problem around the world. The discovery of the hepatitis C virus has diverted interest from hepatitis B to this new virus and the epidemic associated with it, but hepatitis B remains a significant pathogen for millions of people worldwide. The World Health Organization has suggested that universal vaccination of children against hepatitis B should be implemented in an attempt to reduce the enormous morbidity and mortality associated with infection of this virus group. The review seeks to identify all the newer discoveries relating to hepatitis B that have been made in the past decade. Reference is made to the appearance of hepatitis B mutants which are able to infect patients previously infected with the wild strain of the virus. The implications of mutants on vaccination programmes is raised, as are issues relating to treatment of hepatitis B infection.

show abstract

Hepatitis B Virus-Related Polyarteritis Nodosa and Membranous Nephropathy

Cited by 16 publications

References 13 publications

Renal Impairment in Chronic Hepatitis B: A Review

Renal Impairment in Chronic Hepatitis B: A Review

Biologic Immunomodulatory Therapies in the Vasculitic Diseases

Hepatitis B

Contact Info

Product

Resources

About